{"id":"filgrastim-sd-01","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"null","effect":"Splenomegaly"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Filgrastim binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and activation. This results in increased neutrophil production and mobilization into peripheral blood, helping to prevent or reduce the severity of chemotherapy-induced neutropenia and its associated infections.","oneSentence":"Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:44.996Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia in cancer patients"},{"name":"Mobilization of peripheral blood progenitor cells for stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":"RUNX1 Familial Platelet Disorder","enrollment":4},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":"Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","enrollment":994},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":"Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":140},{"nctId":"NCT04383743","phase":"PHASE2","title":"Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-24","conditions":"Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma","enrollment":17},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT05032183","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":"Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":"AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","enrollment":46},{"nctId":"NCT02014675","phase":"","title":"SD01 Registry (SD01 ICD Lead)","status":"COMPLETED","sponsor":"Biotronik SE & Co. KG","startDate":"2014-03","conditions":"Ventricular Fibrillation, Ventricular Tachycardia, Heart Failure","enrollment":280},{"nctId":"NCT01836497","phase":"","title":"SD01 Master Study (Safety and Efficacy Study)","status":"COMPLETED","sponsor":"Biotronik SE & Co. KG","startDate":"2013-05","conditions":"Ventricular Tachycardia, Ventricular Fibrillation, Heart Failure","enrollment":163},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT00304070","phase":"PHASE3","title":"Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-05-03","conditions":"Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7","enrollment":78},{"nctId":"NCT00004192","phase":"PHASE2","title":"Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-05-01","conditions":"Lymphoma, Neutropenia","enrollment":60},{"nctId":"NCT00679029","phase":"PHASE2","title":"Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2008-05-02","conditions":"HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer","enrollment":15},{"nctId":"NCT04156828","phase":"PHASE1","title":"Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-03-31","conditions":"Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma","enrollment":12},{"nctId":"NCT01256398","phase":"PHASE2","title":"Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":66},{"nctId":"NCT03518112","phase":"PHASE2","title":"Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-04-18","conditions":"Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":6},{"nctId":"NCT00063999","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"GOG Foundation","startDate":"2003-08-25","conditions":"Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7","enrollment":1381},{"nctId":"NCT00478361","phase":"PHASE2","title":"Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04","conditions":"Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer","enrollment":40},{"nctId":"NCT01012297","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11","conditions":"Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma","enrollment":107},{"nctId":"NCT01533207","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"2012-06-04","conditions":"Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma","enrollment":38},{"nctId":"NCT00004853","phase":"PHASE1","title":"Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-03-03","conditions":"Ewing's Sarcoma, Rhabdomyosarcoma, MPNST","enrollment":34},{"nctId":"NCT01266447","phase":"PHASE2","title":"Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma","enrollment":27},{"nctId":"NCT03551769","phase":"PHASE1","title":"Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production","status":"COMPLETED","sponsor":"Cerecin","startDate":"2018-08-05","conditions":"Alzheimer Disease","enrollment":20},{"nctId":"NCT00063934","phase":"PHASE1, PHASE2","title":"Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-05","conditions":"Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer","enrollment":31},{"nctId":"NCT00038558","phase":"PHASE3","title":"Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-11","conditions":"Hodgkin Disease","enrollment":25},{"nctId":"NCT00038545","phase":"PHASE2","title":"A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-05-18","conditions":"Non-Hodgkin's Lymphoma","enrollment":25},{"nctId":"NCT02650635","phase":"PHASE1","title":"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-02-05","conditions":"Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma","enrollment":4},{"nctId":"NCT01557959","phase":"PHASE2","title":"Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2007-07","conditions":"Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer","enrollment":45},{"nctId":"NCT01654965","phase":"PHASE1","title":"Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-24","conditions":"Adult Solid Neoplasm","enrollment":17},{"nctId":"NCT01682044","phase":"PHASE2","title":"Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2007-04-17","conditions":"Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma","enrollment":20},{"nctId":"NCT03063645","phase":"PHASE1","title":"Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production","status":"COMPLETED","sponsor":"Cerecin","startDate":"2017-03-11","conditions":"Healthy","enrollment":17},{"nctId":"NCT00031629","phase":"PHASE2","title":"Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2005-01","conditions":"Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma","enrollment":51},{"nctId":"NCT00006011","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2000-07","conditions":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma","enrollment":659},{"nctId":"NCT00352300","phase":"PHASE1","title":"Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2006-06","conditions":"Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia","enrollment":43},{"nctId":"NCT00433537","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-05","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma","enrollment":77},{"nctId":"NCT00119262","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-10","conditions":"Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer","enrollment":226},{"nctId":"NCT01639521","phase":"PHASE2","title":"Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2013-05","conditions":"Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer","enrollment":""},{"nctId":"NCT00075634","phase":"PHASE1","title":"Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-12","conditions":"Recurrent Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":21},{"nctId":"NCT00086944","phase":"PHASE1, PHASE2","title":"Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-05","conditions":"Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":25},{"nctId":"NCT00050674","phase":"PHASE2","title":"Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Schwartzberg, Lee, M.D.","startDate":"2001-11","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT00035620","phase":"PHASE2","title":"Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-04","conditions":"Sarcoma, Neutropenia","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["G-CSF","Neupogen"],"phase":"phase_3","status":"active","brandName":"Filgrastim SD/01","genericName":"Filgrastim SD/01","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts. Used for Chemotherapy-induced neutropenia in cancer patients, Mobilization of peripheral blood progenitor cells for stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}